Skip to main content
. 2015 Aug 18;10(8):e0135867. doi: 10.1371/journal.pone.0135867

Fig 1. MiR-200c is highly expressed in tumor-associated MDSCs.

Fig 1

(A and B) Expression of mature (A) and primary (B) miR-200c in CD11b+Gr-1+ cells isolated from the bone marrow of mice with different tumors. Ctrl-C57, B16 and Lewis were respectively CD11b+Gr1+ cells from tumor-free C57BL/6 mice, C57BL/6 mice bearing B16 melanoma and C57BL/6 bearing Lewis lung cancer; Ctrl-Balb andCT-26 were respectively CD11b+Gr1+ cells from tumor-free Balb/c mice and Balb/c mice with CT-26 tumor. (C and D) Expression of mature (C) and primary (D) miR-200c in tumor cell conditioned medium (TCCM) treated BM cells. BM cells were cultured with TCCM from B16 melanoma (B16), CT-26 colon cancer (CT-26), ID8 ovarian cancer (1D8) or 4T1 breast cancer (4T1, 25% v/v) for 36 h. (E) Expression of miR-200c in BM cells treated by different doses of TCCM. BM cells were treated with serial dilution of 4T1 TCCM for 36 h. 10, 20 and 50% indicated the concentrations of TCCM in medium. Each experiment was independently performed three times. *, p<0.05; **, P<0.01.